Press release
Overactive Bladder Pipeline Insight 2025: Next-Gen Neuromodulation, Beta-3 Agonists, and Regenerative Therapies Redefine Bladder Control | DelveInsight
Overactive Bladder Pipeline Insight
Leading candidates include Urovant Sciences' vibegron, a beta-3 adrenergic agonist with favorable tolerability, and Axonics Modulation Technologies' sacral neuromodulation device, which offers wireless, recharge-free bladder control. On the regenerative side, Lipella Pharmaceuticals is developing LP-10, a liposomal botulinum formulation designed to prolong bladder relaxation with minimal invasiveness. Novel targets such as P2X3 antagonists, TRP channel blockers, and even microbiome-based therapies are entering early-stage trials, offering fresh avenues for intervention.
Beyond pharmacology, digital therapeutics, wearable sensors, and AI-driven voiding diaries are being incorporated into trial protocols to personalize treatment regimens. The FDA's focus on patient-reported outcomes, especially around social functioning and sleep impact, is also shaping regulatory expectations. With multimodal innovation converging across devices, drugs, and diagnostics, the OAB pipeline is primed to disrupt a stagnant market and dramatically enhance treatment adherence and efficacy.
Interested in learning more about the current treatment landscape and the key drivers shaping the overactive bladder pipeline? Click here: https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Overactive Bladder Pipeline Report
• DelveInsight's overactive bladder pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for overactive bladder treatment.
• The leading overactive bladder companies include Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics, and others are evaluating their lead assets to improve the overactive bladder treatment landscape.
• Key overactive bladder pipeline therapies in various stages of development include DA-8010, Neuronox, URO-902, TAC-302, Solabegron, and others.
• In December 2024, FemPulseTM announced FDA approval for its Investigational Device Exemption (IDE) to launch the EVANESCE II pivotal clinical trial for female patients with overactive bladder (OAB), marking the first application of FemPulse's patented female health platform.
Request a sample and discover the recent breakthroughs happening in the overactive bladder pipeline landscape at https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Overactive Bladder Overview
Overactive bladder (OAB) is a common condition characterized by a sudden, uncontrollable urge to urinate, often accompanied by frequent urination and, in some cases, urge incontinence (involuntary leakage). It results from abnormal bladder muscle contractions that cause the bladder to empty prematurely, even when it is not full. OAB affects people of all ages but is more prevalent in older adults and can significantly impact quality of life.
Causes of OAB may include neurological disorders, bladder inflammation, urinary tract infections, or unknown factors. Diagnosis typically involves patient history, physical examination, and sometimes bladder function tests. Treatment options range from lifestyle changes and pelvic floor exercises to medications that relax the bladder muscles. In more severe cases, advanced therapies like nerve stimulation or Botox injections may be considered.
Find out more about overactive bladder medication at https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Overactive Bladder Treatment Analysis: Drug Profile
Neuronox: AbbVie/Medytox
Neuronox, developed by Medytox, is an acetylcholine inhibitor containing Clostridium botulinum toxin type A, intended for the treatment of Overactive Bladder (OAB). It is currently in Phase III development. In September 2020, Allergan entered a licensing agreement with Medytox, agreeing to pay an upfront fee of USD 65 million and securing exclusive rights to develop and commercialize certain neurotoxin candidates, including a potential liquid-injectable product, outside of Korea. In May 2020, AbbVie completed its acquisition of Allergan after receiving all necessary regulatory approvals and court clearance.
URO-902: Urovant Sciences
Urovant Sciences is developing URO-902, a potential first-in-class gene therapy for Overactive Bladder. This innovative treatment targets patients who have not responded to oral medications and are concerned about the risks of urinary retention or surgery associated with current third-line therapies. URO-902 is currently in Phase II clinical development.
Learn more about the novel and emerging overactive bladder pipeline therapies at https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Overactive Bladder Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule
Scope of the Overactive Bladder Pipeline Report
• Coverage: Global
• Key Overactive Bladder Companies: Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics, and others.
• Key Overactive Bladder Pipeline Therapies: DA-8010, Neuronox, URO-902, TAC-302, Solabegron, and others.
To dive deep into rich insights for drugs used for overactive bladder treatment, visit: https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Overactive Bladder Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Pipeline: Late-Stage Products (Phase III)
7. Overactive Bladder Pipeline: Mid-Stage Products (Phase II)
8. Overactive Bladder Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Overactive Bladder Pipeline Insight 2025: Next-Gen Neuromodulation, Beta-3 Agonists, and Regenerative Therapies Redefine Bladder Control | DelveInsight here
News-ID: 4125178 • Views: …
More Releases from DelveInsight
Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunothe …
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and progression through targeted and immune-based therapies, and (2) improve patient survival, quality of life, and functional outcomes. Current programs include EGFR, ALK, KRAS, and MET inhibitors, immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), and emerging bispecific antibodies and combination regimens designed to overcome resistance and enhance efficacy.
Late-stage…
Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve sheath tumors (MPNST) while improving quality of life. Current programs include RAS-MAPK pathway inhibitors, next-generation MEK inhibitors, mTOR modulators, immuno-oncology agents for MPNST, and early gene-directed therapies.
Late-stage trials primarily test oral RAS pathway inhibitors for pediatric plexiform neurofibromas, with attention to safety, functional improvement, and…
Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through next-generation multivalent and protein-based vaccines, and (2) improve long-term immunity and reduce disease incidence in adolescents, young adults, and high-risk populations. Ongoing programs include conjugate vaccines, adjuvanted formulations, and combination vaccines targeting meningococcal and other pediatric pathogens to optimize immunization schedules.
Late-stage and pivotal trials focus…
Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor control, and (2) enhance patient quality of life and daily functioning. Ongoing programs include small-molecule pharmacologics targeting GABAergic and calcium channel pathways, focused ultrasound neuromodulation, deep brain stimulation (DBS) refinements, and emerging gene therapy candidates aimed at long-term tremor suppression.
Late-stage and registration-enabling trials assess efficacy,…
More Releases for Overactive
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Top Factor Driving Overactive Bladder Treatment Market Growth in 2025: Geriatric …
What industry-specific factors are fueling the growth of the overactive bladder treatment market?
The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
Overactive Bladder Market Report, History and Forecast 2022-2030
Overactive Bladder Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Overactive Bladder industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, …
Market Analysis and Insights of Overactive Bladder Treatment Market
During the forecasted period of 2023-2032, the market for treatments for overactive bladder will grow at a CAGR of about 4.00%. The main drivers of the overactive bladder treatment market's expansion are the rising prevalence of kidney-related disorders, increased emphasis on medical device research and development expertise and the adoption of cutting-edge IT healthcare technologies, an increasing geriatric population worldwide, and rising…
